915385-81-8,MFCD22666355
Catalog No.:AA00H0QJ

915385-81-8 | ABC294640

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$31.00   $22.00
- +
5mg
98%
in stock  
$96.00   $68.00
- +
25mg
98%
in stock  
$331.00   $232.00
- +
100mg
98%
in stock  
$573.00   $401.00
- +
250mg
98%
in stock  
$835.00   $584.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00H0QJ
Chemical Name:
ABC294640
CAS Number:
915385-81-8
Molecular Formula:
C23H25ClN2O
Molecular Weight:
380.9104
MDL Number:
MFCD22666355
SMILES:
Clc1ccc(cc1)C12CC3CC(C1)CC(C2)(C3)C(=O)NCc1ccncc1
Properties
Computed Properties
 
Complexity:
551  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
27  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0  
Rotatable Bond Count:
4  
Undefined Atom Stereocenter Count:
2  
Undefined Bond Stereocenter Count:
0  
XLogP3:
4.7  

Downstream Synthesis Route

[1]CurrentPatentAssignee:APOGEEBIOTECHNOLOGYCORPORATION;EHPOUDZHIBIOTEKNOLODZHI-US2006/287317,2006,A1Locationinpatent:Page/Pagecolumn34-35

[1]CurrentPatentAssignee:APOGEEBIOTECHNOLOGYCORPORATION;EHPOUDZHIBIOTEKNOLODZHI-US2006/287317,2006,A1Locationinpatent:Page/Pagecolumn34-35

CASUnavailable 
  56531-62-5    915385-81-8 

[1]CurrentPatentAssignee:TIANJINMINXIANGPHARMACEUTICALCOLTD-CN116217468,2023,ALocationinpatent:Paragraph0054-0062

Literature

Title: Elevated Nuclear and Cytoplasmic FTY720-Phosphate in Mouse Embryonic Fibroblasts Suggests the Potential for Multiple Mechanisms in FTY720-Induced Neural Tube Defects.

Journal: Toxicological sciences : an official journal of the Society of Toxicology 20160301

Title: Effect of alkyl chain length on sphingosine kinase 2 selectivity.

Journal: Bioorganic & medicinal chemistry letters 20121115

Title: Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.

Journal: Experimental biology and medicine (Maywood, N.J.) 20120701

Title: Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.

Journal: Thrombosis and haemostasis 20120301

Title: Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion.

Journal: Journal of hepatology 20120101

Title: Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats.

Journal: PloS one 20120101

Title: Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

Journal: Investigational new drugs 20111201

Title: Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase.

Journal: Inflammopharmacology 20110401

Title: Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.

Journal: Cancer biology & therapy 20110401

Title: Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

Journal: Cancer biology & therapy 20110301

Title: Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2.

Journal: Pharmacology 20110101

Title: Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

Journal: Endocrinology 20101101

Title: Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase.

Journal: Carcinogenesis 20101001

Title: A novel sphingosine kinase inhibitor induces autophagy in tumor cells.

Journal: The Journal of pharmacology and experimental therapeutics 20100501

Title: Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease.

Journal: Inflammopharmacology 20100401

Title: Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases.

Journal: Investigative ophthalmology & visual science 20061101

Title: French KJ, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010 Apr;333(1):129-39.

Title: Beljanski V, et al. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs. 2011 Dec;29(6):1132-42.

Title: Shi Y, et al. Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion. J Hepatol. 2012 Jan;56(1):137-45.

Title: Liu Q, et al. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS One. 2012;7(7):e41834.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 915385-81-8
Historical Records
Tags:915385-81-8 Molecular Formula|915385-81-8 MDL|915385-81-8 SMILES|915385-81-8 ABC294640
Catalog No.: AA00H0QJ
915385-81-8,MFCD22666355
915385-81-8 | ABC294640
Pack Size: 1mg
Purity: 98%
in stock
$31.00 $22.00
Pack Size: 5mg
Purity: 98%
in stock
$96.00 $68.00
Pack Size: 25mg
Purity: 98%
in stock
$331.00 $232.00
Pack Size: 100mg
Purity: 98%
in stock
$573.00 $401.00
Pack Size: 250mg
Purity: 98%
in stock
$835.00 $584.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00H0QJ
Chemical Name: ABC294640
CAS Number: 915385-81-8
Molecular Formula: C23H25ClN2O
Molecular Weight: 380.9104
MDL Number: MFCD22666355
SMILES: Clc1ccc(cc1)C12CC3CC(C1)CC(C2)(C3)C(=O)NCc1ccncc1
Properties
Complexity: 551  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 0  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 27  
Hydrogen Bond Acceptor Count: 2  
Hydrogen Bond Donor Count: 1  
Isotope Atom Count: 0  
Rotatable Bond Count: 4  
Undefined Atom Stereocenter Count: 2  
Undefined Bond Stereocenter Count: 0  
XLogP3: 4.7  
Downstream Synthesis Route
3731-53-1    1057292-87-1    915385-81-8 

[1]CurrentPatentAssignee:APOGEEBIOTECHNOLOGYCORPORATION;EHPOUDZHIBIOTEKNOLODZHI-US2006/287317,2006,A1Locationinpatent:Page/Pagecolumn34-35

3731-53-1    1057292-88-2    915385-81-8 

[1]CurrentPatentAssignee:APOGEEBIOTECHNOLOGYCORPORATION;EHPOUDZHIBIOTEKNOLODZHI-US2006/287317,2006,A1Locationinpatent:Page/Pagecolumn34-35

CASUnavailable 
  56531-62-5    915385-81-8 

[1]CurrentPatentAssignee:TIANJINMINXIANGPHARMACEUTICALCOLTD-CN116217468,2023,ALocationinpatent:Paragraph0054-0062

Literature fold

Title: Elevated Nuclear and Cytoplasmic FTY720-Phosphate in Mouse Embryonic Fibroblasts Suggests the Potential for Multiple Mechanisms in FTY720-Induced Neural Tube Defects.

Journal: Toxicological sciences : an official journal of the Society of Toxicology20160301

Title: Effect of alkyl chain length on sphingosine kinase 2 selectivity.

Journal: Bioorganic & medicinal chemistry letters20121115

Title: Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.

Journal: Experimental biology and medicine (Maywood, N.J.)20120701

Title: Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice.

Journal: Thrombosis and haemostasis20120301

Title: Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion.

Journal: Journal of hepatology20120101

Title: Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats.

Journal: PloS one20120101

Title: Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.

Journal: Investigational new drugs20111201

Title: Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase.

Journal: Inflammopharmacology20110401

Title: Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.

Journal: Cancer biology & therapy20110401

Title: Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.

Journal: Cancer biology & therapy20110301

Title: Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of sphingosine kinase-2.

Journal: Pharmacology20110101

Title: Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

Journal: Endocrinology20101101

Title: Suppression of colitis-driven colon cancer in mice by a novel small molecule inhibitor of sphingosine kinase.

Journal: Carcinogenesis20101001

Title: A novel sphingosine kinase inhibitor induces autophagy in tumor cells.

Journal: The Journal of pharmacology and experimental therapeutics20100501

Title: Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease.

Journal: Inflammopharmacology20100401

Title: Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases.

Journal: Investigative ophthalmology & visual science20061101

Title: French KJ, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010 Apr;333(1):129-39.

Title: Beljanski V, et al. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs. 2011 Dec;29(6):1132-42.

Title: Shi Y, et al. Sphingosine kinase-2 inhibition improves mitochondrial function and survival after hepatic ischemia-reperfusion. J Hepatol. 2012 Jan;56(1):137-45.

Title: Liu Q, et al. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. PLoS One. 2012;7(7):e41834.

Building Blocks More >
861440-59-7
861440-59-7
4-Bromo-2-phenyloxazole
AA00H0YK | MFCD12828098
913375-27-6
913375-27-6
4-(TRIETHOXYSILYLPROPOXY)-2,2,6,6-TETRAMETHYLPIPERIDINE N-OXIDE, tech-85
AA00H1EG
91538-82-8
91538-82-8
1-Bromo-4-(trans-4-ethylcyclohexyl)benzene
AA00H1PI | MFCD08275628
886362-16-9
886362-16-9
2,4-Di-tert-Butyl-6-(((2-((3,5-di-tert-butyl-2-methylbenzyl)(methyl)amino)ethyl)(methyl)amino)methyl)phenol
AA00H1X2 | MFCD08056682
90929-73-0
90929-73-0
Ethanone, 2-bromo-1-(1H-pyrrolo[2,3-b]pyridin-3-yl)-
AA00H249 | MFCD09265687
866611-29-2
866611-29-2
9-Bromo-10-[4-(2-naphthyl)phenyl]anthracene
AA00H2OF | MFCD20486476
913848-94-9
913848-94-9
4-(1H-Pyrazol-1-yl)aniline hydrochloride
AA00H30C | MFCD06738875
872785-39-2
872785-39-2
1-benzyl-2,3-dihydro-1H-indene-1-carboxylic acid
AA00H3PY | MFCD21230195
904013-52-1
904013-52-1
N-(3-Aminophenyl)isonicotinamide
AA00H4H0 | MFCD00626063
930837-03-9
930837-03-9
(R)-Benzyl 3-(hydroxymethyl)piperazine-1-carboxylate
AA00H5C7 | MFCD09954308
Submit
© 2017 AA BLOCKS, INC. All rights reserved.